CureVac N.V. is a biopharmaceutical entity operating in the clinical development phase, focused on pioneering revolutionary medicines utilizing messenger ribonucleic acid (mRNA) technology. Its portfolio includes prophylactic vaccines such as the mRNA-based candidate CV2CoV, currently in Phase 1 clinical trials for SARS-CoV-2. Another mRNA vaccine, CV7202, has successfully concluded Phase 1 trials for rabies, while CVSQIV is in Phase 1 development against influenza. The company is also advancing therapies for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. Furthermore, CureVac is actively developing RNA-based immunotherapies for cancer, exemplified by CV8102, which is presently in Phase 1 clinical evaluation for cutaneous melanoma, adenoidcystic carcinoma, and squamous cell cancers affecting the skin, head, and neck. The company was established in 2000 and maintains its main office in Tübingen, Germany.